Beth Israel Deaconess Medical Center : Proteomic Profiling Shown More Accurate Than Traditional Biomarkers In Identifying Liver Cancer
Published: Jan 16, 2008
As the incidence of liver cancer continues to grow-- fueled in large part, by rising rates of hepatitis C infections -- so too does the need for tests to help diagnose the disease at an earlier stage. A study appearing in the January 15 issue of Clinical Cancer Research demonstrates that a novel mass-spectrometry based form of proteomic profiling is more accurate than traditional biomarkers in distinguishing liver cancer patients from patients with hepatitis C liver cirrhosis, particularly with regard to identifying patients with small, curable tumors. Led by researchers at Beth Israel Deaconess Medical Center (BIDMC), the study could help lead to earlier diagnostic methods -- and subsequent treatments -- for liver cancer.